The HIV+Hepatitis Policy Institute strongly urges the Advisory Committee on Immunization Practices (ACIP) to maintain the recommendation of a universal hepatitis B birth dose in the United States. Maintaining this requirement will not only help prevent people from becoming ill but result in ending hepatitis B in our country, which is still a highly infectious disease.
Comments to Oregon PDAB on PBM reform, transparency, and increasing prescription drug access
As a national patient advocacy organization that works to promote quality and affordable healthcare for individuals living with or at risk of HIV, hepatitis, and other chronic conditions, we see firsthand how PBM practices, pharmacy access, and insurance design determine whether patients can remain on lifesaving treatment. We appreciate the Board’s continued focus on practical, patient-centered reforms that Oregon can move forward with.
Oregon PDAB comments on Rx affordability and transparency
These recommendations will help ensure that savings flow directly to patients, preserve access to community and safety-net pharmacies, and strengthen programs like 340B that sustain care for vulnerable populations. Oregon’s leadership in advancing practical, patient-focused solutions can serve as a model for other states seeking to balance affordability with access and innovation. Thank you for the opportunity to comment and for your ongoing leadership on behalf of Oregon patients. We look forward to supporting the Board’s work as these recommendations move forward to the legislature.
Comment to HRSA on enrollment and re-certification of entities in the 340B drug pricing program
The HIV+Hepatitis Policy Institute submits this comment in support of HRSA’s proposed documentation and registration updates for Sexually Transmitted Disease (STD) grantees and subgrantees participating in the 340B Drug Pricing Program. STI clinics are a key setting for HIV testing and prevention services, including PrEP and PEP, as well as for testing and treatment for viral hepatitis, especially hepatitis C. As longstanding advocates for the 340B program, we believe strong oversight and clear documentation are critical to preserving its integrity and ensuring it continues to serve its core mission: supporting safety net providers and expanding access to care for low-income and underserved populations, including people with or at risk of HIV and hepatitis.
Comments on Washington PDAB affordability reviews of HIV medications
As the Board finalizes its list of prescription drugs to review, we want to reiterate our concerns about the inclusion of HIV and hepatitis medications and encourage the Board to reconsider their inclusion. We believe that affordability reviews of HIV medications fail to fully account for the intricacies of the existing HIV safety net, which makes lifesaving HIV treatments affordable for most people. We also want to highlight numerous factors in the global HIV drug ecosystem that would be difficult for a state to effectively consider.